Under-eye filler versus PRF versus lower blepharoplasty

Under-eye filler, platelet-rich fibrin, and lower blepharoplasty do not solve the same problem. Filler places volume, PRF uses an autologous blood-derived preparation with less certain aesthetic evidence, and surgery can reposition or remove fat and address skin or lid structure.

The lower eyelid can look tired for several independent reasons, and a single person may have more than one. A hollow can cast a shadow; protruding orbital fat can create a bag; thin skin can reveal vessels; pigment can darken the surface; laxity and edema can change the contour. Filler, PRF, and surgery intervene in different layers, so diagnosis-by-menu is especially unreliable here. ¹²³

Map the lower-eyelid problem first

Lower-eyelid anatomy can combine hollowing, fat prolapse, skin excess, laxity, pigment, visible vessels, edema, and midface descent. A route becomes coherent only after the dominant feature is named.

Hyaluronic-acid filler adds material. In a selected hollow or sharp lid-cheek transition, carefully placed volume may reduce shadowing. It cannot remove excess skin, strengthen a lax lower lid, erase pigment, or take away prolapsed fat. In an eye area already prone to fluid retention, adding hydrophilic material can make puffiness more noticeable or persist longer than expected.

PRF starts with the patient’s blood and creates a platelet- and fibrin-containing preparation whose final form depends on tubes, centrifugation, timing, and handling. Clinics may inject a liquid preparation or use a fibrin matrix while describing both as PRF. It does not place a standardized volumizing implant and should not be quoted as a predictable milliliter-for-milliliter correction; it also cannot surgically reposition a fat pad or tighten a weak lid.

Lower blepharoplasty is an operation rather than an injectable substitute. Depending on anatomy and technique, a surgeon may remove or reposition fat, address skin, and support related structures. That broader structural reach comes with anesthesia choices, postoperative swelling and bruising, scars, activity restrictions, and risks that require a surgical consultation.

Compare evidence that matches the target

Filler studies report satisfaction but use variable techniques and mostly lower-level evidence; no needle-versus-cannula superiority has been established. PRF protocols differ in collection tubes, spin parameters, activation, dose, and endpoints, limiting product-to-product comparison.

The tear-trough filler literature reviewed in the cited systematic review includes reported satisfaction and improvement, but techniques, products, follow-up, and study quality vary. It does not establish a universally superior needle or cannula approach, an ideal amount for every anatomy, or freedom from delayed edema and vascular complications. A clinic’s result gallery can illustrate style; it cannot supply the denominator or adverse-event follow-up of a study.

The 2026 periorbital systematic review found high reported satisfaction, moderate effectiveness for hyperpigmentation, and mixed objective findings for wrinkles and texture. ⁴ Preparation varied enough to limit clear conclusions. Those findings do not establish predictable under-eye volume replacement or a preferred PRF protocol, so a quote should state spin force and time, tubes, final form and volume, sessions, injection plane, and the exact measured endpoint.

Blepharoplasty evidence addresses surgical techniques and complications, not a guarantee of a perfectly smooth lid. The cited review emphasizes that lower-lid surgery has multiple approaches and risk profiles. Surgeon assessment of lid tone, eye-surface symptoms, fat position, skin, midface support, prior procedures, and medical history is more informative than ranking “downtime” alone.

Regulatory labels do not make the routes equivalent

FDA approves individual filler products for particular indications and anatomical regions; it does not approve “under-eye filler” as one blanket procedure. Ask to see the exact filler and whether the tear-trough or proposed plane follows its labeling. An off-label placement may be used in practice, but it should be named as such rather than borrowing approval from a different approved facial indication.

An autologous preparation is not automatically an FDA-approved treatment for under-eye rejuvenation. The regulatory status of collection and preparation devices is distinct from proof that the resulting PRF protocol improves a specific cosmetic endpoint. Surgery is evaluated through the standard of the operative plan, facility, anesthesia, and clinician qualifications rather than being marketed as a device clearance.

Material risks and response planning

The under-eye is a high-consequence area. Filler can cause persistent swelling, contour irregularity, color change, nodules, and rare vascular injury including blindness. Surgery has its own risks, including bleeding, dry eye, asymmetry, lid malposition, scarring, and revision.

For filler, discuss bruising, swelling, contour irregularity, visible or bluish material, nodules, infection, and the possibility of persistent edema. Rare inadvertent intravascular injection can cause skin injury, vision loss, or stroke. A credible plan identifies the filler material and lot, has hyaluronidase available when HA is used, and gives explicit instructions for severe pain, blanching or discoloration, or any visual or neurologic symptom.

PRF avoids an implanted manufactured gel but still involves venipuncture and injection. Pain, bruising, infection, tissue injury, and inconsistent response remain possible. Adding microneedling, filler, exosomes, vitamins, or another substance creates a combined procedure with a different risk and evidence profile; it should not be counted as proof of PRF alone.

Surgical questions include bleeding, infection, dry eye, chemosis, asymmetry, scarring, prolonged swelling, lid retraction or ectropion, vision-threatening complications, and possible revision. Bring a history of dry-eye symptoms, eye surgery, contact-lens intolerance, thyroid eye disease, anticoagulants, smoking, and prior filler. The surgeon should explain who provides urgent postoperative care and where the operation takes place.

Questions for three different consultations

1. 1. Which anatomical feature creates most of the shadow or bag? Ask the clinician to point it out at rest, in profile, and with gentle lid movement rather than saying only “tired eyes.”
2. 2. What exact material or operation would address it? For filler, name the product and amount; for PRF, document processing; for surgery, describe fat, skin, and support steps.
3. 3. What will this route leave unchanged? A strong answer acknowledges pigment, edema, skin, fat, hollowing, or laxity that falls outside the proposed intervention.
4. 4. Does old filler alter the plan? Discuss whether records, examination, imaging, dissolving, or a waiting interval would improve assessment before adding or operating.
5. 5. What does the recovery calendar include? Compare visible swelling, bruising, work and exercise restrictions, follow-up visits, and the window for judging the final contour.
6. 6. Who handles eye-related warning signs? Obtain day-and-night instructions for visual change, severe pain, bleeding, exposure symptoms, or postoperative lid-position problems.

Use durability only after fit is established

Ask the clinician to point to the feature being treated in standardized photographs and explain what the proposed route cannot change. Prior filler matters to surgical planning; bring product names and dates rather than relying on memory that something was “dissolved.”

Filler can be performed quickly, yet persistent swelling or an ill-fitting contour can make its true burden much longer than the appointment. PRF is often sold as natural, but multiple blood draws and sessions with an uncertain magnitude of change are still a commitment. Surgery has a larger initial recovery and different risks, while offering access to excess skin, fat position, and lid structure that injections cannot directly correct.

The sensible sequence follows anatomy. Someone with a modest hollow and stable lid may compare conservative filler with observation. Someone primarily concerned about skin quality can ask whether a defined PRF protocol has evidence for that endpoint. Pronounced fat prolapse, skin excess, or support problems justify an oculoplastic or plastic-surgery evaluation before repeated camouflage.

End with side-by-side standardized photographs and a one-sentence target such as “soften this lid-cheek shadow without increasing morning puffiness” or “address this fat bulge and skin excess.” If a proposed route cannot plausibly deliver that sentence, its convenience or popularity does not rescue the match.